Having related persons affected by cancer also did not have an impact as reported previously, patients with self-experience with cancer did not have higher utilities (they do not rate the given scenarios more positively because they had already experienced and managed situations of toxicity) but showed higher threshold benefits for the chance of being melanoma-free at 5 years after adjuvant IFNa-2b treatment with mild-to-moderate side effects (60.7% versus 50.7% on average, p=.011). Here, IFNA1 is linked to melanoma.